NCT06999551尚未招募4 期
Comparison of the Efficacy and Safety of GLARGEN® Versus NPH Insulin in the Treatment of Diabetes Type 2, in Tunisian Patients.
适应症
干预措施
相关药物
试验速览
- 阶段
- 4 期
- 状态
- 尚未招募
- 入组人数
- 60
- 试验地点
- 1
- 主要终点
- glycaemic variability on insulin glargine (after 12 weeks of use) versus NPH insulin (baseline)
研究概览
简要总结
This study will have a single arm: the patient on NPH will continue his treatment for 4 weeks, at the end of the NPH treatment, the patient will receive his CGM device for three days for glycemic holter, a switch to insulin glargine is started for a period of 12 weeks with a dose adjustment and a control of the glycemic balance by CGM for three days at the end of the study.
The NPH insulin vial is a 10 ml vial dosed at 100 IU/mL, The Glargen vial is in the form of a solution for injection, a 3 ml vial dosed at 100 IU/mL
详细描述
Follow-up visits will include :
- V0: - 4 weeks: Screening visit (before the start of treatment): patients will be selected at this initial visit, if they meet all the inclusion criteria and none of the non-inclusion criteria, the patient will receive the glucometer. The patient presents himself to do his initial assessment (including HbA1c) and sign the consent, to do his therapeutic education and to receive the nutrition booklet
- V1: -3 weeks: the patient will be contacted by the ARC (phone call) to communicate the results of the glycemic cycle already performed and for titration of his NPH, continue with the new dose until the monitoring stops
- V2: inclusion visit: D0: 4 weeks later, the patient will receive his CGM. A glycemic cycle will be done and communicated to the ARC.
- V3: Visit of 4 weeks + 07 days: the day the patient presents himself to put the CGM device back on (stop monitoring) and collect data (glycemic holter under NPH) and switch to insulin glargine.
- V4 + V5: respectively at 2 and 3 weeks after switching to insulin glargine, the CRA contacts the patient by phone to record the results of the glycemic cycle and thus adapt the dose of insulin glargine upwards or downwards as needed (titration). The patient will do a glycemic cycle and communicate it to their ARC. Continue with the new dose until the next V6 titration
- V6: at 6 weeks after switching to insulin glargine, the patient will attend the consultation (face-to-face) to communicate the results of the corresponding glycemic cycle and thus adapt the dose of insulin glargine upwards or downwards as needed (titration). Continue with the new dose until monitoring is stopped
- V7: 12 weeks after starting glargine, the patient presents again for placement of the CGM device (start of monitoring). The patient will also do a glycemic cycle at the same time and communicate it to his ARC. A laboratory assessment (including glycated hemoglobin) will be requested.
- V8: 12 weeks + 7 days stop CGM monitoring (collection of holter results under glargine) and end of the study.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 70 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age≥ 18 and <70
- •Type 2 diabetic patients, with a duration of NPH between 5 and 10 years.
- •Patients treated with a double dose of NPH insulin with a stable dose of insulin and a stable dose of ADO (oral antidiabetic drugs) for at least 2 months prior to the start of the study.
- •An HbA1c level between 7% and 10%
- •Ability to use a continuous glucose monitoring (CGM) system and cycle blood glucose with the meter.
- •Written informed consent obtained prior to participation in the study.
排除标准
- •Pregnant and breastfeeding women
- •Patients with active proliferative and/or complicated diabetic retinopathy, treated by photocoagulation or surgically, within 6 months prior to study entry or any other rapidly progressing unstable retinopathy that may require photocoagulation or surgery during the study (plan to perform fundus prior to inclusion).
- •History of insulin glargine hypersensitivity
- •Treatment with systemic, neuroleptic, immunosuppressive and antiretroviral corticosteroids within 3 months prior to study entry and during the study and other treatments, which may significantly affect blood glucose.
- •Severe renal impairment at baseline defined by a < 30ml/min.
- •Patients on sulfonylurea drugs or glinides or on more than three oral antidiabetic drugs (ODAs)
- •Patients on rapid insulin.
- •Patients Enrolled in Other Clinical Studies
- •Patients who refuse to sign consent.
研究组 & 干预措施
patient receiving NPH insulin
Experimental
evaluating safety and efficacy after switching the patient receiving NPH into glargin insulin.
干预措施: switch NPH to glargin (Drug)
结局指标
主要结局
glycaemic variability on insulin glargine (after 12 weeks of use) versus NPH insulin (baseline)
时间窗: 4 months
compare glycaemic variability on insulin glargine (after 12 weeks of use) versus NPH insulin (baseline) using the CGM device generating the area under the curve in the range, above the range, below the range in type 2 diabetic patients treated with NPH basal insulin alone or in combination with oral antidiabetic drugs.
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
已完成
3 期
PGL4001 Versus GnRH-agonist in Uterine MyomasUterine MyomasNCT00740831PregLem SA301
已完成
2 期
An 8-week Study to Evaluate Safety and Efficacy of NGF Eye Drops Solution Versus Vehicle in Patients With Dry EyeDry EyeNCT03019627Dompé Farmaceutici S.p.A150
已完成
不适用
Clinical Evaluation of Safety and Efficacy for the NEUROMARK System in Subjects With Chronic Rhinitis (PARAGON)Chronic RhinitisNCT05591989Neurent Medical80
已完成
不适用
Phase III Clinical Trial to Evaluate the Efficacy and Safety of HNP-2001 in Surgical Patients undergoing General AnesthesiaKCT0002786Hana Pharm198
已完成
3 期
A Study of Pegylated Interferon Alfa-2a and Lamivudine in Patients With HBeAg-Negative Chronic Hepatitis B Virus (HBV)Hepatitis B, ChronicNCT01095835Hoffmann-La Roche131